Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Over the past five years, Novavax ( NVAX 6.01%), a vaccine maker, lost more than 90% of its market value. Though it succeeded ...

As part of the deal, Repertoire Immune Medicines will develop up to three drug candidates that target the drivers of certain autoimmune diseases.

Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Baseline Therapeutics, Inc. (baseline-tx.com) is a San Francisco-based clinical-stage biotechnology company developing breakthrough therapeutics for addiction. Baseline's lead program, BT-001, is a ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.

Pfizer is also making strides in the weight management market. It now owns one of the more promising mid-stage assets in this ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.